NASDAQ:VCNX Vaccinex (VCNX) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free VCNX Stock Alerts $5.93 +0.93 (+18.60%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$5.40▼$5.9550-Day Range$4.76▼$12.2552-Week Range$4.43▼$100.80Volume8,465 shsAverage Volume11,528 shsMarket Capitalization$7.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Vaccinex alerts: Email Address Vaccinex MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.99% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.00Based on 2 Articles This WeekInsider TradingAcquiring Shares$1,334 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.93 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Vaccinex. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.99% of the float of Vaccinex has been sold short.Short Interest Ratio / Days to CoverVaccinex has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaccinex has recently increased by 157.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVaccinex does not currently pay a dividend.Dividend GrowthVaccinex does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VCNX. Previous Next 2.8 News and Social Media Coverage News SentimentVaccinex has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vaccinex this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for VCNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Vaccinex to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaccinex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,334.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders51.50% of the stock of Vaccinex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.11% of the stock of Vaccinex is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaccinex is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaccinex is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Vaccinex Stock (NASDAQ:VCNX)Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.Read More VCNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCNX Stock News HeadlinesApril 14, 2024 | investing.comVaccinex faces Nasdaq compliance challengeApril 2, 2024 | investorplace.comVCNX Stock Earnings: Vaccinex Reported Results for Q4 2023April 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 2, 2024 | globenewswire.comVaccinex Reports 2023 Financial Results and Provides Corporate UpdateMarch 27, 2024 | globenewswire.comVaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMarch 6, 2024 | investing.comVaccinex CFO Scott Royer to retire, Jill Sanchez steps inMarch 2, 2024 | morningstar.comVaccinex Inc VCNXFebruary 21, 2024 | finanznachrichten.deVaccinex, Inc.: Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus TechnologyApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 21, 2024 | markets.businessinsider.comVaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery PlatformFebruary 21, 2024 | finance.yahoo.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 21, 2024 | globenewswire.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 15, 2024 | markets.businessinsider.comVaccinex Announces 1-For-14 Reverse Stock SplitFebruary 15, 2024 | msn.comWhy Vaccinex (VCNX) Stock Is Trading LowerFebruary 15, 2024 | globenewswire.comVaccinex, Inc. Announces Reverse Stock SplitFebruary 12, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex IncFebruary 8, 2024 | msn.comVaccinex Inc Secures $3.7M in Private Placement DealFebruary 7, 2024 | msn.comWhy Vaccinex (VCNX) Stock Is Popping OffFebruary 7, 2024 | markets.businessinsider.comVaccinex Announces Pricing of $3.7 Million PIPE FinancingDecember 4, 2023 | finance.yahoo.comNasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing RuleNovember 13, 2023 | finance.yahoo.comVaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 31, 2023 | finance.yahoo.comVaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual MeetingOctober 26, 2023 | finance.yahoo.comVaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative DiseasesOctober 6, 2023 | markets.businessinsider.comWhy Is Vaccinex (VCNX) Stock Up 26% Today?September 29, 2023 | finanznachrichten.deVaccinex, Inc.: Vaccinex Announces Pricing of $9.6 Million Public OfferingSeptember 29, 2023 | marketwatch.comVaccinex Shares Slide Premarket After Stock OfferingSeptember 29, 2023 | finance.yahoo.comVaccinex Announces Pricing of $9.6 Million Public OfferingSee More Headlines Receive VCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/02/2024Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VCNX CUSIPN/A CIK1205922 Webwww.vaccinex.com Phone(585) 271-2700Fax585-271-2765Employees38Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($100.8610) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,250,000.00 Net MarginsN/A Pretax Margin-3,552.81% Return on Equity-2,667.31% Return on Assets-571.70% Debt Debt-to-Equity RatioN/A Current Ratio0.57 Quick Ratio0.57 Sales & Book Value Annual Sales$570,000.00 Price / Sales11.80 Cash FlowN/A Price / Cash FlowN/A Book Value($2.59) per share Price / Book-2.11Miscellaneous Outstanding Shares1,230,000Free Float598,000Market Cap$6.73 million OptionableNo Data Beta0.74 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Maurice Zauderer Ph.D. (Age 78)Co-Founder, CEO, President & Director Comp: $400.7kDr. Elizabeth E. Evans Ph.D. (Age 52)COO and Senior VP of Discovery & Translational Medicine Comp: $255.46kDr. Ernest S. Smith Ph.D. (Age 52)Senior VP of Research & Chief Scientific Officer Comp: $284.02kMs. Jill Sanchez (Age 52)Controller, Interim CFO, Principal Financial Officer & Principal Accounting Officer Dr. John E. Leonard Ph.D. (Age 77)Senior Vice President of Development Key CompetitorsAinosNASDAQ:AIMDAvenue TherapeuticsNASDAQ:ATXIXenetic BiosciencesNASDAQ:XBIOFirst Wave BioPharmaNASDAQ:FWBIHoth TherapeuticsNASDAQ:HOTHView All CompetitorsInsiders & InstitutionsAlbert FriedbergBought 282 shares on 4/19/2024Total: $1,333.86 ($4.73/share)AIGH Capital Management LLCSold 273,112 shares on 2/12/2024Ownership: 6.542%Worth Venture Partners LLCSold 63,480 shares on 2/9/2024Ownership: 5.237%Strydonck Gerald E. VanSold 224 sharesTotal: $2,257.92 ($10.08/share)Albert FriedbergBought 214,285 shares on 10/3/2023Total: $3.00 M ($14.00/share)View All Insider TransactionsView All Institutional Transactions VCNX Stock Analysis - Frequently Asked Questions How have VCNX shares performed in 2024? Vaccinex's stock was trading at $9.3072 at the start of the year. Since then, VCNX stock has decreased by 36.3% and is now trading at $5.93. View the best growth stocks for 2024 here. Are investors shorting Vaccinex? Vaccinex saw a increase in short interest in April. As of April 15th, there was short interest totaling 16,200 shares, an increase of 157.1% from the March 31st total of 6,300 shares. Based on an average trading volume of 13,200 shares, the short-interest ratio is currently 1.2 days. Approximately 3.0% of the company's stock are sold short. View Vaccinex's Short Interest. When is Vaccinex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our VCNX earnings forecast. How were Vaccinex's earnings last quarter? Vaccinex, Inc. (NASDAQ:VCNX) announced its quarterly earnings data on Tuesday, April, 2nd. The company reported ($39.40) earnings per share (EPS) for the quarter. When did Vaccinex's stock split? Shares of Vaccinex reverse split before market open on Tuesday, February 20th 2024. The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Vaccinex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX). When did Vaccinex IPO? Vaccinex (VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager. How do I buy shares of Vaccinex? Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VCNX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.